Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 3/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KRAS | P01116 | 3/20 | 0.43 |
| ▸ | NCEH1 | Q6PIU2 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20808986 | 0.85 | LMNA (0.44) | KDM4ELMNAITGB3ITGA2BGRIN2B | |
| SCHEMBL20786908 | 0.83 | ITGB3 (0.51) | PSMB1PSMB5POLBKDM4ENTSR1 | |
| SCHEMBL20808938 | 0.82 | PSMB1 (0.48) | PSMB1PSMB5POLBKRASKDM4E | |
| SCHEMBL24248536 | 0.82 | NLRP3 (0.40) | PSMB1PSMB5POLBKDM4ELMNA | |
| SCHEMBL21025176 | 0.82 | GRIN2B (0.40) | KDM4EITGB3ITGA2BGRIN2BMAPT | |
| SCHEMBL20786879 | 0.82 | TNF (0.51) | PSMB1PSMB5POLBKDM4ELMNA | |
| SCHEMBL20786929 | 0.81 | PSMB1 (0.57) | PSMB1PSMB5POLBKRASKDM4E | |
| SCHEMBL20786895 | 0.79 | PSMB1 (0.61) | PSMB1PSMB5POLBKDM4ENTSR1 | |
| SCHEMBL1500208 | 0.78 | PSMB1 (0.43) | PSMB1PSMB5POLBKDM4ELMNA | |
| SCHEMBL20786925 | 0.78 | HTR2C (0.44) | PSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3453707-B1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3453707-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2019-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | TLR8, TLR1, TLR5 | PSMB1 3284/4885PSMB5 2461/4885POLB 4281/4885 |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | TLR8, TLR1, TLR5 | PSMB1 3284/4885PSMB5 2461/4885POLB 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.